Key Takeaways
- • 410 Medical, a Durham, NC-based medical device company, completed a $12 million Series funding round led by Orlando Health Ventures with participation from nine additional investors including health systems and venture firms.
- • The company's flagship product, LifeFlow®, received FDA clearance in 2016 and is used to enhance administration of fluids and blood products for patients with sepsis, hemorrhagic shock, and other critical conditions.
- • The investor syndicate includes both healthcare-focused venture firms (Hatteras Venture Partners) and direct strategic participation from major health systems (Orlando Health, Ballad Health, OSF Healthcare, Tampa General), signaling strong clinical validation and distribution pathways.
- • Founded in 2013, 410 Medical focuses on advanced resuscitation technologies for emergency and critical care settings where clinical intervention timing is mission-critical.
- • An undisclosed strategic investor participated in the round, suggesting potential strategic partnership or acquisition interest from a larger healthcare or medical device player.
Summary
410 Medical announced completion of a $12 million financing round on July 14, 2026, marking a significant capital raise for the North Carolina-based medical device company specializing in emergency and critical care technologies. Orlando Health Ventures led the round, with participation from a diversified investor base spanning venture capital firms, regional health systems, and one unnamed strategic investor.
The company's core asset is LifeFlow®, a FDA-cleared device launched in 2016 designed to optimize the delivery of intravenous fluids and blood products to critically ill patients. The technology targets high-acuity applications including sepsis management, hemorrhagic shock resuscitation, and other life-threatening conditions where rapid and precise fluid administration can materially impact patient outcomes. Founded in 2013, 410 Medical positions itself at the intersection of emergency medicine and resuscitation science, focusing on clinical scenarios where intervention timing is measured in minutes.
The funding syndicate composition reflects both financial and strategic confidence in the company's market opportunity. The participation of major health systems—including Orlando Health, Ballad Health, OSF Healthcare, Tampa General, and CU Healthcare Innovations Fund—indicates these institutions view the technology as clinically differentiated and operationally compatible with their emergency departments and critical care units. This health system investment structure often signals dual benefit: capital deployment combined with potential distribution advantages and clinical validation within participating networks.
The inclusion of specialized healthcare venture firms (Hatteras Venture Partners), health system-affiliated venture arms (Catalyst by Wellstar, Rex Health Ventures), and supply chain partners (Sarnova) suggests a capital structure designed to accelerate both clinical adoption and commercial scaling. The undisclosed strategic investor may represent either a larger medical device manufacturer evaluating partnership or acquisition options, or a healthcare private equity firm positioning for future consolidation in the resuscitation technology segment.
The company's core asset is LifeFlow®, a FDA-cleared device launched in 2016 designed to optimize the delivery of intravenous fluids and blood products to critically ill patients. The technology targets high-acuity applications including sepsis management, hemorrhagic shock resuscitation, and other life-threatening conditions where rapid and precise fluid administration can materially impact patient outcomes. Founded in 2013, 410 Medical positions itself at the intersection of emergency medicine and resuscitation science, focusing on clinical scenarios where intervention timing is measured in minutes.
The funding syndicate composition reflects both financial and strategic confidence in the company's market opportunity. The participation of major health systems—including Orlando Health, Ballad Health, OSF Healthcare, Tampa General, and CU Healthcare Innovations Fund—indicates these institutions view the technology as clinically differentiated and operationally compatible with their emergency departments and critical care units. This health system investment structure often signals dual benefit: capital deployment combined with potential distribution advantages and clinical validation within participating networks.
The inclusion of specialized healthcare venture firms (Hatteras Venture Partners), health system-affiliated venture arms (Catalyst by Wellstar, Rex Health Ventures), and supply chain partners (Sarnova) suggests a capital structure designed to accelerate both clinical adoption and commercial scaling. The undisclosed strategic investor may represent either a larger medical device manufacturer evaluating partnership or acquisition options, or a healthcare private equity firm positioning for future consolidation in the resuscitation technology segment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.